Effect of the addition of montelukast to inhaled fluticasone propionate on airway inflammation

American Journal of Respiratory and Critical Care Medicine

Volumn 167, Issue 5, 2003, Pages 745-750

  O' Sullivan, Siobhán ^a   Akveld, Martijn ^b   Burke, Conor M ^b   Poulter, Leonard W ^b  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b NONE

Author keywords

Asthma; Fluticasone; Inflammation; Montelukast

Indexed keywords

AUTACOID; CD45 ANTIGEN; FLUTICASONE PROPIONATE; GAMMA INTERFERON; INTERLEUKIN 4; MONTELUKAST; PLACEBO; ACETIC ACID DERIVATIVE; ANDROSTANE DERIVATIVE; ANTIASTHMATIC AGENT; ANTIINFLAMMATORY AGENT; BRONCHODILATING AGENT; FLUTICASONE; GLUCOCORTICOID; LEUKOTRIENE RECEPTOR BLOCKING AGENT; QUINOLINE DERIVATIVE;

ADULT; ARTICLE; ASTHMA; BLOOD CELL COUNT; BRONCHUS BIOPSY; BRONCHUS MUCOSA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; EOSINOPHIL; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; LUNG FUNCTION TEST; LYMPHOCYTE COUNT; MALE; MAST CELL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFLAMMATION; T LYMPHOCYTE; BIOPSY; BRONCHUS; COMPARATIVE STUDY; DRUG COMBINATION; INFLAMMATION; INHALATIONAL DRUG ADMINISTRATION; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; STATISTICAL ANALYSIS; TIME; TOPICAL DRUG ADMINISTRATION;

ACETATES; ADMINISTRATION, INHALATION; ADMINISTRATION, TOPICAL; ADULT; ANDROSTADIENES; ANTI-ASTHMATIC AGENTS; ANTI-INFLAMMATORY AGENTS; ASTHMA; BIOPSY; BRONCHI; BRONCHODILATOR AGENTS; CROSS-OVER STUDIES; DATA INTERPRETATION, STATISTICAL; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FORCED EXPIRATORY VOLUME; GLUCOCORTICOIDS; HUMANS; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INTERFERON TYPE II; INTERLEUKIN-4; LEUKOTRIENE ANTAGONISTS; MALE; MIDDLE AGED; PLACEBOS; QUINOLINES; TIME FACTORS;

EID: 0037364283     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/rccm.200208-783OC     Document Type: Article

References (33)

1. Vignola AM, Chanez P, Campbell AM, Souques F, Lebel B, Enander I, Bousquet J. Airway inflammation in mild intermittent and in persistent asthma. Am J Respir Crit Care Med 1998;157:403-409.
2. Global Strategy for Asthma Management and Prevention. National Heart, Lung and Blood Institute Report. National Institutes of Health; Revised 2002.
3. Barnes P. Current issues for establishing inhaled corticosteroids as the antiinflammatory agents of choice in asthma. J Allergy Clin Immunol 1998;101:S427-S433.
4. Djukanovic R, Wison J, Britten K, Wilson SJ, Walls AF, Roche WR, Howarth PH, Holgate ST. Effect of an inhaled corticosteroid on airway inflammation and symptoms in asthma. Am Rev Respir Dis 1992;145:669-674.
5. Drazen JM, Isreal E. Should antileukotriene therapies be used instead of inhaled corticosteroids in asthma? Yes. Am J Respir Crit Care Med 1998;158:1699-1705.
6. Laviolette M, Malmstrom K, Lu S, Chervinsky P, Pujet JC, Peszek I, Zhang J, Reiss TF. Montelukast added to inhaled beclomethasone in treatment of asthma. Am J Respir Crit Care Med 1999;160:1862-1868.
7. Busse WW. Leukotrienes and inflammation. Am J Respir Crit Care Med 1998;157:S210-S213.
8. 4 and granulocytic infiltration into asthmatic airways. Lancet 1993;341:989-990.
9. Gauvreau GM, Parameswaran KN, Watson RM, O'Byrne PM. Inhaled leukotriene E(4), but not leukotriene D(4), increased airway inflammatory cells in subjects with atopic asthma. Am J Respir Crit Care Med 2001;564:1495-1500.
10. Barnes NC. Effects of antileukotrienes in the treatment of asthma. Am J Respir Crit Care Med 2000;161:S73-S76.
11. Reiss TF, Chervinsky P, Dockhorn RJ, Shingo S, Seidenberg B, Edwards TB. Montelukast, a once-daily leukotriene receptor antagonist in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Arch Intern Med 1998;158:1213-1220.
12. Cristian-Virchow JC, Prasse A, Naya I, Summerton L, Harris A. Zafirlukast improves asthma control in patients receiving high-dose inhaled corticosteroids. Am J Respir Crit Care Med 2000;562:578-585.
13. Lofdahl CG, Reiss TF, Leff JA, Isreal E, Noonan MJ, Seidenberg AF, Capizzi T, Kundu S, Godard P. Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients. BMJ 1999;319:87-90.
14. Tamaoki J, Kondo M, Sakai N, Nakata J, Takemura H, Nagai A, Takizawa T, Konno K. Leukotriene antagonist prevents exacerbation of asthma during reduction of high-dose inhaled corticosteroid: The Tokyo Joshi-Idai Asthma Research Group. Am J Respir Crit Care Med 1997;155:1235-1240.
15. Yoshida S, Ishizaki Y, Shoji T, Onuma K, Nakagawa H, Nakabayashi M, Akahori K, Hasegawa H, Amayasu H. Effect of pranlukast on bronchial inflammation in patients with asthma. Clin Exp Allergy 2000;30:1008-1014.
16. Pizzichini E, Leff JA, Reiss TF, Hendeles L, Boulet L-P, Wei LX, Efthimiadis AE, Zhang J, Hargreave FE. Montelukast reduces airway eosinophilic inflammation in asthma: a randomized, controlled trial. Eur Respir J 1999;14:12-18.
17. Calhoun WJ, Lavins BJ, Minkwitz MC, Evans R, Gleich GJ, Cohn J. Effect of zafirlukast (Accolate) on cellular mediators of inflammation: bronchoalveolar lavage fluid findings after segmental allergen challenge. Am J Respir Crit Care Med 1998;157:1385-1389.
18. Bisgaard H, Loland L, Oj JA. NO in exhaled air of asthmatic children is reduced by the leukotriene receptor antagonist montelukast. Am J Respir Crit Care Med 1999;160:1227-1231.
19. Nakamura Y, Hoshino M, Sim JJ, Ishii K, Hosaka K, Sakamoto T. Effect of the leukotriene receptor antagonist pranlukast on cellular infiltration in the bronchial mucosa of patients with asthma. Thorax 1998;53:835-841.
20. Burke C, Sreenan S, Pathmakanthan S, Patterson J, Schmekel B, Poulter LW. Relative effects of inhaled corticosteroids on immunopathology and physiology in asthma: a controlled study. Thorax 1996;51:993-999.
21. Sont JK, Willems LN, Evertse CE, Hooijer R, Sterk PJ, van Krieken JH. Repeatability of measures of inflammatory cell number in bronchial biopsies in atopic asthma. Eur Respir J 1997;10:2602-2608.
22. Olivieri D, Chetta A, Del Donno M. Effect of short-term treatment with low-dose inhaled fluticasone propionate on airway inflammation and remodeling in mild asthma: a placebo controlled study. Am J Respir Crit Care Med 1997;155:1864-1871.
23. Faul J, Leonard C, Burke C, Poulter LW. Fluticasone propionate induced alterations to lung function and the immunopathology of asthma over time. Thorax 1998;53:753-761.
24. O'Sullivan S, Cormican L, Murphy M, Poulter LW, Burke CM. Effects of varying doses of inhaled corticosteroids on the physiology and bronchial wall immunopathology in mild to moderate asthma. Chest 2002;122:1966-1972.
25. Pauwels RA, Lofdahl CG, Postma DS, Tattersfield AE, O'Byrne P, Barnes PJ, Ullman A. Effect of inhaled formoterol and budesonide on exacerbations of asthma: Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 1997;337:1405-1411.
26. Louis R, Lau LC, Bron AO, Roldaan AC, Radermecker M, Djukanovic R. The relationship between airways inflammation and asthma severity. Am J Respir Crit Care Med 2000;161:9-16.
27. Holma R, Salmenpera P, Riutta A, Virtanen I, Korpela R, Vapaatalo H. Acute effects of the cys-leukotriene-1 receptor antagonist, montelukast, on experimental colitis in rats. Eur J Pharmacol 2001;429:309-318.
28. Dempsey OJ, Wilson AM, Sims EJ, Mistry C, Lipworth BJ. Additive bronchoprotective and bronchodilator effects with single doses of salmeterol and montelukast in asthmatic patients receiving inhaled corticosteroids. Chest 2000;117:950-953.
29. Dempsey OJ, Fowler SJ, Wilson A, Kennedy G, Lipworth BJ. Effects of adding either a leukotriene receptor antagonist or low-dose theophylline to a low or medium dose of inhaled corticosteroid in patients with persistent asthma. Chest 2002;122:151-159.
30. Minoguchi K, Kohno Y, Minoguchi H, Kihara N, Sano Y, Yasuhara H, Adachi M. Reduction of eosinophilic inflammation in the airways of patients with asthma using montelukast. Chest 2002;121:732-738.
31. Wilson AM, Dempsey OJ, Sims EJ, Lipworth BJ. Evaluation of salmeterol or montelukast as second-line therapy for asthma not controlled with inhaled corticosteroids. Chest 2001;119:1021-1026.
32. Vidal C, Fernandez-Ovide E, Pineiro J, Nunez R, Gonzalez-Quintela A. Comparison of montelukast versus budesonide in the treatment of exercise-induced bronchoconstriction. Ann Allergy Asthma Immunol 2001;86:655-658.
33. Dahlen SE, Malmstrom K, Nizankowska E, Dahlen B, Kuna P, Kowalski M, Lumry WR, Picado C, Stevenson DD, Bousquet J, et al. Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial. Am J Respir Crit Care Med 2002;165:9-14.